How to buy Cannabics Pharmaceuticals stock (Cannabics Pharmaceuticals)

Cannabics Pharmaceuticals is a biotechnology business based in the US. Cannabics Pharmaceuticals shares (CNBX) are listed on the PINK and all prices are listed in US Dollars. Its last market close was $0.01 – the same closing value as a week prior.

Our top picks for where to buy Cannabics Pharmaceuticals stock

Buy Cannabics Pharmaceuticals stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Cannabics Pharmaceuticals stock price (PINK: CNBX)

Use our graph to track the performance of CNBX stocks over time.

Cannabics Pharmaceuticals shares at a glance

• Key figures

Information last updated 2024-12-26.

Latest market close	$0.01
52-week range	$0.01 - $0.02
50-day moving average more info button	$0.01
200-day moving average more info button	$0.01
Wall St. target price	N/A
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-0.02

Cannabics Pharmaceuticals price performance over time

Historical closes compared with the close of $0.01 from 2024-12-26

1 week (2024-12-20)	0.01
1 month (2024-11-27)	0.01
3 months (2024-09-27)	0.01
6 months (2024-06-28)	75.44%

1 year (2023-12-28)	-28.57%
2 years (2022-12-28)	-99.61%
3 years (2021-12-28)	10.224
5 years (2019-12-27)	9.348

Cannabics Pharmaceuticals financials

Revenue TTM	$230,074
Gross profit TTM	$7,157
Return on assets TTM	-116.59%
Return on equity TTM	-4289.36%
Profit margin	0%
Book value	$-0.08
Market Capitalization more info button	$311,114

TTM: trailing 12 months

Cannabics Pharmaceuticals share dividends

We're not expecting Cannabics Pharmaceuticals to pay a dividend over the next 12 months.

You may also wish to consider:

• Amgen (AMGN.US) (3.61% forward annual dividend yield)

Have Cannabics Pharmaceuticals's shares ever split?

Cannabics Pharmaceuticals's shares were split on a 1:120 basis on 11 May 2022 . So if you had owned 120 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cannabics Pharmaceuticals shares – just the quantity. However, indirectly, the new 11900% higher share price could have impacted the market appetite for Cannabics Pharmaceuticals shares which in turn could have impacted Cannabics Pharmaceuticals's share price.

Cannabics Pharmaceuticals share price volatility

Over the last 12 months, Cannabics Pharmaceuticals's shares have ranged in value from as little as $0.005 up to $0.0184. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (PINK average) beta is 1, while Cannabics Pharmaceuticals's is 0.793. This would suggest that Cannabics Pharmaceuticals's shares are less volatile than average (for this exchange).

To put Cannabics Pharmaceuticals's beta into context you can compare it against those of similar companies.

• Regeneron Pharmaceuticals (REGN.US): 0.142
• Exelixis (EXEL.US): 0.511
• Amgen (AMGN.US): 0.599

Cannabics Pharmaceuticals overview

CNBX Pharmaceuticals Inc. , a clinical stage company, engages in the discovery, development, and commercialization of novel cannabinoid-based products and technologies for the treatment of cancer. Its lead product candidate is Cannabics SR, an oral capsule developed for the treatment of patients with advanced cancer and cancer anorexia cachexia syndrome. The company is also developing various drug candidates, including PLP-33 for the treatment of lateral spreading or sessile, and colorectal polyps during colonoscopy; BRST-33 to treat breast cancer; MLN-33 for the treatment of Melanoma; and PRST-33 to treat prostate cancer. In addition, it is developing RCC-33, an oral capsule containing a formulation of cannabinoids for the treatment of colorectal cancer; and Cannabics CDx, an ex-vivo drug sensitivity test. The company was formerly known as Cannabics Pharmaceuticals Inc. and changed its name to CNBX Pharmaceuticals Inc.

Frequently asked questions

null
What percentage of Cannabics Pharmaceuticals is owned by insiders or institutions?
Currently 2.332% of Cannabics Pharmaceuticals shares are held by insiders and 3.26% by institutions. When does the fiscal year end for Cannabics Pharmaceuticals?
Cannabics Pharmaceuticals's fiscal year ends in August. Where is Cannabics Pharmaceuticals based?
Cannabics Pharmaceuticals's address is: #3 Bethesda Metro Center, Bethesda, MD, United States, 20814 What is Cannabics Pharmaceuticals's ISIN number?
Cannabics Pharmaceuticals's international securities identification number is: US13764M1009